Zepbound (Tirzepatide) Constipation Severity Grading: A Clinical Rubric for Patients and Providers

What a Formal Grade Describes

The National Cancer Institute's CTCAE is an adverse-event classification system. The current version 6.0 constipation entry distinguishes occasional symptoms, persistent symptoms, obstipation and life-threatening consequences. Its definitions use treatment requirements and daily function, rather than a universal two-, three- or five-day bowel movement threshold. [2]

The table below explains the four grades discussed in this article. It is an excerpt for understanding the terminology, rather than the complete CTCAE document or evidence that the same grading rules were used in every SURMOUNT trial or every FAERS report.

Instrumental activities and self-care describe different levels of function. Report what is difficult in daily life instead of assigning a grade solely from a calendar. A clinician or trial team applies the relevant grading framework in context. [2]

A Symptom Record Is Different From a Home Grading Algorithm

Record stool frequency and consistency, straining, incomplete evacuation, pain, distension, vomiting and the ability to pass gas. Include how the problem affects eating, usual activities and self-care. Also record products used, their amounts and the response. [3]

A green, yellow and red color scheme is not the formal CTCAE definition or a validated Zepbound protocol. Formal grades do not prescribe a mandatory fiber target, daily PEG-plus-docusate combination, automatic dose hold or a particular imaging test. Treatment and testing depend on the history and examination. [2, 3]

Trial Incidence Is Not a Severity Distribution

The current Zepbound label reports pooled constipation rates of 17%, 14% and 11% at 5 mg, 10 mg and 15 mg, versus 5% with placebo. These rates are not a breakdown of mild, moderate and severe constipation. They do not establish an 80/15/5 severity distribution or a steadily increasing dose-response pattern. [1]

Different SURMOUNT trials have different populations and designs. The pooled label table should not be relabeled as a constipation severity table or used to invent a grade-specific discontinuation rate. The sources reviewed here do not verify a claim that no grade 4 constipation occurred throughout the entire trial program.

Postmarketing Reports Do Not Supply a Reliable Percentage

The Zepbound label includes reports of ileus, intestinal obstruction and severe constipation with fecal impaction. Because voluntary reports have an uncertain denominator and other limitations, frequency and causation cannot reliably be established from them. They do not validate a claimed count of 3,847 reports, a reporting-odds ratio or a percentage of serious cases without the underlying analysis. [1]

Treatment Evidence Should Be Kept Separate

The joint AGA/ACG guideline supports PEG for CIC, conditionally supports fiber with evidence for psyllium, and includes rescue and prescription treatments. CIC evidence is different from an opioid-induced constipation guideline and from a tested Zepbound severity-based regimen. [4]

Zepbound maintenance selection takes response and tolerability into account. A formal grade does not automatically instruct someone to continue, hold or reduce the next dose. The symptom history and actual evaluation determine the treatment discussion. [1]

The existing symptoms described here, including severe pain, distension, vomiting, inability to pass gas, rectal bleeding or prolonged inability to pass stool, warrant prompt attention. A self-assigned mild grade should not be used to dismiss worsening symptoms. [1, 3]